Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
NCT00151333
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
SRA-333
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer